MedTrace Logo

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

NCT03968744 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-03-13

No results posted yet for this study

Summary

Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Conditions

  • Idiopathic Parkinson's Disease (at Later Stage)

Interventions

DRUG

Safinamide

Safinamide taken per Os for 12 weeks

Sponsors & Collaborators

  • Clinical Trial Unit Ente Ospedaliero Cantonale

    collaborator OTHER

  • Alain Kaelin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2026-02-02
Completion
2026-02-02

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968744 on ClinicalTrials.gov